Papadopoulou Athina, Derfuss Tobias, Sprenger Till
Department of Neurology, University Hospital Basel & University of Basel, Basel, Switzerland.
Medical Image Analysis Center AG, c/o University Hospital Basel, Basel, Switzerland.
Neurodegener Dis Manag. 2017 Oct;7(5):279-297. doi: 10.2217/nmt-2017-0023. Epub 2017 Aug 29.
Daclizumab is a monoclonal antibody that targets the α-chain of the IL-2 receptor. Results of Phase II and III clinical trials showed efficacy of daclizumab in relapsing-remitting multiple sclerosis, with reduction of annualized relapse rate by 50-54% versus placebo and 45% versus intramuscular IFN-β-1a. Certain aspects of the immunomodulatory mode of action of daclizumab were only discovered during its clinical development, such as the expansion of a subpopulation of natural killer cells. In this article, we outline the putative mechanisms of action and the key clinical data on daclizumab, with a focus on the efficacy and safety profile. We also evaluate its potential role in future treatment algorithms of multiple sclerosis.
达克珠单抗是一种靶向白细胞介素-2受体α链的单克隆抗体。II期和III期临床试验结果显示，达克珠单抗对复发缓解型多发性硬化症有效，与安慰剂相比年化复发率降低50-54%，与肌肉注射干扰素β-1a相比降低45%。达克珠单抗免疫调节作用方式的某些方面是在其临床开发过程中才发现的，比如自然杀伤细胞亚群的扩增。在本文中，我们概述了达克珠单抗的推定作用机制和关键临床数据，重点关注其疗效和安全性。我们还评估了它在未来多发性硬化症治疗方案中的潜在作用。
